Profile data is unavailable for this security.
About the company
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
- Revenue in USD (TTM)1.53bn
- Net income in USD-214.69m
- Incorporated2007
- Employees3.28k
- LocationNatera Inc13011 MCCALLEN PASSBUILDING A SUITE 100AUSTIN 78753United StatesUSA
- Phone+1 (650) 249-9090
- Fax+1 (302) 674-5266
- Websitehttps://www.natera.com/
Mergers & acquisitions
Acquired company | NTRA:NSQ since announced | Transaction value |
---|---|---|
Invitae Corp-Reproductive Health Assets | 154.00% | 52.50m |